Macquarie Group
ESPR

Macquarie Group’s Esperion Therapeutics ESPR Stock Holding History

Macquarie Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,215
Closed -$25 – 1975
2024
Q1 		$25 Buy
+9,215
New +$22.4K ﹤0.01% 1679
2021
Q4 		– Sell
-976
Closed -$12K – 2618
2021
Q3 		$12K Hold
976
– – ﹤0.01% 2523
2021
Q2 		$21K Hold
976
– – ﹤0.01% 2351
2021
Q1 		$27K Sell
976
-390
-29% -$11.5K ﹤0.01% 2217
2020
Q4 		$36K Hold
1,366
– – ﹤0.01% 2110
2020
Q3 		$51K Hold
1,366
– – ﹤0.01% 1950
2020
Q2 		$70K Buy
+1,366
New +$57.2K ﹤0.01% 1850
2018
Q3 		– Sell
-16,395
Closed -$642K – 2185
2018
Q2 		$642K Sell
16,395
-35,364
-68% -$1.79M ﹤0.01% 1291
2018
Q1 		$3.74M Buy
51,759
+31,048
+150% +$2.28M 0.01% 835
2017
Q4 		$1.36M Sell
20,711
-2,618
-11% -$141K ﹤0.01% 1146
2017
Q3 		$1.17M Sell
23,329
-2,220
-9% -$107K ﹤0.01% 1159
2017
Q2 		$1.18M Buy
+25,549
New +$940K ﹤0.01% 1117

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's ESPR Position: Q2 2024 in Review

Macquarie Group sold out of Esperion Therapeutics (ESPR) in Q2 2024, closing a stake of 9,215 shares — an estimated $25 sold.

Macquarie Group first reported a position in ESPR in Q2 2017 and held it in 12 quarters. The position peaked at $3.74M in Q1 2018. 176 funds tracked by Wall St. Rank hold ESPR as of Q2 2024.

  • Macquarie Group reported no remaining Esperion Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 9,215 Esperion Therapeutics shares in Q2 2024, an estimated $25.
  • Macquarie Group first reported a position in Esperion Therapeutics in Q2 2017 and held it in 12 quarters.
  • Macquarie Group's Esperion Therapeutics position peaked at $3.74M in Q1 2018.
  • 176 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.